Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. (ACRV) priced its initial public offering on Nov 16, 2022 at $12.50 per share, below its $16.00–$18.00 range, raising $94.4M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $260.7M. Jefferies was lead-left underwriter, joined by TD Cowen and Piper Sandler. Cooley advised the company and Goodwin Procter advised the underwriters.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses a proteomics-based patient responder identification platform to match each medicine to patients whose tumors are predicted to be sensitive to it.

Status

IPO

Ticker

ACRV

Exchange

Nasdaq Global Market

Priced

Nov 16, 2022

IPO price

$12.50

Price range

$16.00–$18.00

Raised

$94.4M

Market cap at IPO price

$260.7M

First filed

Oct 17, 2022

Underwriters

Jefferies, TD Cowen and Piper Sandler

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.